Search Results - "Burmester, Gerd R."

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p293-297. 5p.

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p221-222. 2p.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Authors: Burmester, Gerd R. Stigler, Jayne Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p737-753. 17p.

Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors.

Authors: Mandecka, Anna Perlak, Karolina Bajek, Wiktoria et al.

Source: CTS: Clinical & Translational Science. Mar2026, Vol. 19 Issue 3, p1-8. 8p.

Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA).

Authors: Pongratz, Georg Alten, Rieke Witte, Torsten et al.

Source: Rheumatology & Therapy. Apr2026, Vol. 13 Issue 2, p435-449. 15p.

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Authors: Burmester, Gerd R. Winthrop, Kevin Blanco, Ricardo et al.

Source: Rheumatology & Therapy. Apr2022, Vol. 9 Issue 2, p521-539. 19p.

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Dec2023, Vol. 10 Issue 6, p1575-1595. 21p.

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Oct2023, Vol. 10 Issue 5, p1255-1276. 22p.

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.

Authors: Combe, Bernard G. Tanaka, Yoshiya Buch, Maya H. et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p71-72. 2p.

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p73-93. 21p.

Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).

Authors: Koehm, Michaela Foldenauer, Ann C. Rossmanith, Tanja et al.

Source: Journal of Clinical Medicine. Dec2022, Vol. 11 Issue 24, p7316. 13p.

Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.

Authors: Charles-Schoeman, Christina Giles, Jon T. Lane, Nancy E. et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p157-175. 19p.

Tofacitinib for rheumatoid arthritis - Authors' reply.

Authors: Burmester, Gerd R Benda, Birgitta Gruben, David et al.

Source: Lancet. 5/25/2013, Vol. 381 Issue 9880, p1812-1813. 2p.

URL: 87807033

PUBLICATIONS OF THE WEEK.

Source: Bookseller; 7/4/2003, Issue 5084, p35, 18p

Intestinal Microbiota Reduction Followed by Fasting Discloses Microbial Triggering of Inflammation in Rheumatoid Arthritis.

Authors: Häupl, Thomas Sörensen, Till Smiljanovic, Biljana et al.

Source: Journal of Clinical Medicine. Jul2023, Vol. 12 Issue 13, p4359. 23p.

Three decades of collaboration in rheumatology: a comprehensive co-authorship network analysis (1994–2023).

Authors: Ogasawara, Naruaki¹ (AUTHOR) n-ogasawara@naika.or.jp

Source: Rheumatology / Reumatologia. 2025, Vol. 63 Issue 2, p68-80. 13p.

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.

Authors: Combe, Bernard G. Tanaka, Yoshiya Buch, Maya H. et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p53-70. 18p.

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.

Authors: Winthrop, Kevin L. Curtis, Jeffrey R. Yamaoka, Kunihiro et al.

Source: Rheumatology & Therapy. Feb2022, Vol. 9 Issue 1, p243-263. 21p.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors: Schnitzer TJ Burmester GR Mysler E et al.

Source: Lancet. 8/21/2004, Vol. 364 Issue 9435, p665-674. 10p.

The Impact of Porphyromonas gingivalis Lipids on Apoptosis of Primary Human Chondrocytes.

Authors: Röhner, Eric Hoff, Paula Matziolis, Georg et al.

Source: Connective Tissue Research. Aug2012, Vol. 53 Issue 4, p327-333. 7p.